A breast cancer pill studied in everyday care, including people whose cancer spread to the brain
Original title: Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This drug is already being given to patients in everyday care.
The short version
A pill called elacestrant helped some people with a type of spread breast cancer for several months before they needed a new treatment.
What was studied. Researchers looked at health records from 281 people with breast cancer that had spread. All had a certain gene change and had already tried other hormone drugs before taking elacestrant.
What they found. In 108 people who had one to two past hormone treatments, the typical time before needing a new treatment was 8.2 months. In 68 people whose cancer had spread to the brain, it was 7.4 months. People who had only one past treatment did the best, at 12.2 months.
What this means, and what it doesn't
What it could mean: For people with this type of breast cancer that has spread, even to the brain, this pill may be a choice to talk about with their doctor. It seemed to help for a good stretch of time.
What it doesn't mean: This is not a cure. The study looked back at records and did not compare the pill to other drugs. It is about breast cancer that spread to the brain, not tumors that start in the brain. Results for any one person may be very different.
Source: PubMed, September 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.